Xiao Min Schebye

455 total citations
8 papers, 314 citations indexed

About

Xiao Min Schebye is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Xiao Min Schebye has authored 8 papers receiving a total of 314 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Immunology, 4 papers in Oncology and 2 papers in Molecular Biology. Recurrent topics in Xiao Min Schebye's work include Immune Cell Function and Interaction (4 papers), Immunotherapy and Immune Responses (3 papers) and Cancer-related Molecular Pathways (2 papers). Xiao Min Schebye is often cited by papers focused on Immune Cell Function and Interaction (4 papers), Immunotherapy and Immune Responses (3 papers) and Cancer-related Molecular Pathways (2 papers). Xiao Min Schebye collaborates with scholars based in United States, United Kingdom and Germany. Xiao Min Schebye's co-authors include Marcel Tanudji, Pengfei Zhou, Gregory M. Chin, David Parry, Carmen Álvarez, Emma Lees, Yonghong Zhu, Ronald J. Doll, Junzhuan Qiu and Cheng‐Chi Chao and has published in prestigious journals such as The Journal of Immunology, Molecular and Cellular Biology and Cancer Research.

In The Last Decade

Xiao Min Schebye

8 papers receiving 308 citations

Peers

Xiao Min Schebye

MB

ONCOL

IMMUN

CB

PS

Judith Vinaixa Spain

Sara Ovejero France

Georgia Velimezi Austria

Kanwaldeep Kaur Rasila United States

Catarina Oliveira United Kingdom

Andrea Ho United States

Katherine Yang‐Iott United States

Sriram Sridharan United States

Jeffrey J. Ackroyd United States

Shruti Malu United States

Judith Vinaixa Spain

Xiao Min Schebye

157 ×0.9

MB

193 ×1.4

ONCOL

162 ×1.4

IMMUN

28 ×0.3

CB

9 ×0.4

PS

Citations per year, relative to Xiao Min Schebye Xiao Min Schebye (= 1×) peers Judith Vinaixa

Countries citing papers authored by Xiao Min Schebye

Since Specialization

Citations

This map shows the geographic impact of Xiao Min Schebye's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiao Min Schebye with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiao Min Schebye more than expected).

Fields of papers citing papers by Xiao Min Schebye

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiao Min Schebye. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiao Min Schebye. The network helps show where Xiao Min Schebye may publish in the future.

Co-authorship network of co-authors of Xiao Min Schebye

This figure shows the co-authorship network connecting the top 25 collaborators of Xiao Min Schebye. A scholar is included among the top collaborators of Xiao Min Schebye based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiao Min Schebye. Xiao Min Schebye is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

Taylor, Matthew H., Aung Naing, John D. Powderly, et al.. (2024). Phase I dose escalation study of IO-108, an anti-LILRB2 antibody, in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer. 12(11). e010006–e010006. 4 indexed citations

2.

Huang, Tao, Kyu Hong, Krista McCutcheon, et al.. (2023). Abstract LB217: A novel bispecific LILRB4/CD3 antibody with potent killing of monocytic acute myeloid leukemia cells. Cancer Research. 83(8_Supplement). LB217–LB217. 1 indexed citations

3.

Taylor, Matthew H., Manish R. Patel, John D. Powderly, et al.. (2023). Abstract CT040: A first-in-human phase 1 trial of IO-108, an antagonist antibody targeting LILRB2 (ILT4), as monotherapy and in combination with pembrolizumab in adult patients with advanced relapsed or refractory solid tumors: Dose escalation study. Cancer Research. 83(8_Supplement). CT040–CT040. 6 indexed citations

4.

Zhou, Pengfei, et al.. (2010). Mature B Cells Are Critical to T-cell-mediated Tumor Immunity Induced by an Agonist Anti-GITR Monoclonal Antibody. Journal of Immunotherapy. 33(8). 789–797. 29 indexed citations

5.

Zhou, Pengfei, et al.. (2007). Pivotal Roles of CD4+ Effector T cells in Mediating Agonistic Anti-GITR mAb-Induced-Immune Activation and Tumor Immunity in CT26 Tumors. The Journal of Immunology. 179(11). 7365–7375. 88 indexed citations

6.

Tanudji, Marcel, et al.. (2006). Unmasking the Redundancy Between Cdk1 and Cdk2 at G2 Phase in Human Cancer Cell Lines. Cell Cycle. 5(9). 984–993. 42 indexed citations

7.

Tanudji, Marcel, et al.. (2004). Gene Silencing of CENP-E by Small Interfering RNA in HeLa Cells Leads to Missegregation of Chromosomes after a Mitotic Delay. Molecular Biology of the Cell. 15(8). 3771–3781. 96 indexed citations

8.

Zhu, Yonghong, Carmen Álvarez, Ronald J. Doll, et al.. (2004). Intra-S-Phase Checkpoint Activation by Direct CDK2 Inhibition. Molecular and Cellular Biology. 24(14). 6268–6277. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact